Esperion Therapeutics Inc at Jefferies Healthcare Conference Transcript
First, my name is Dennis Ding, biotech analyst here at Jefferies. I have the great pleasure of having Esperion Therapeutics here and CEO Sheldon Koenig here with us.
Questions & Answers
Before we dive into some of the updates this year and the tremendous progress the company has made, maybe just to level set all of us in terms of what your messaging is to investors around the development and the path forward?
Great. Well, first of all, thank you, Dennis, and I won't be looking at you when I answer the question. So I'm not being rude. But just so everybody can hear me looking into the microphone. And on behalf of Esperion and all of our employees, we're very excited to be again back at Jefferies. Dennis, really appreciate your support as well and your questions.
So I think the biggest thing for us, as everyone knows, on March 4, we presented the CLEAR outcome study and the study
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
